Bold Update on Bold Stock VCRT:

Huge Release Issued Wednesday on Vicor Technologies (OTCBB: VCRT) – Dell Official Quoted as Vicor Selects Dell as Worldwide IT Hardware Partner for Its PD2i Analyzer(TM)

Dear Members,

It was last December when I brought you Vicor Technologies (OTCBB: VCRT) for the first time. It is a company that has the extraordinary ability to diagnose risk when it comes to reading EKG’s. Now, that greatly simplifies the story. I encourage you to watch the interview we conducted in first quarter of this year. SEE IT HERE ON OUR SHAREHOLDER VISION SITE.

What is extraordinary just yesterday is a press release that show how close the company is to fully commercializing the PD2i Analyzer™ through an newly announced strategic relationship with Dell, Inc. Note that a company as significant as Dell is absolutely not going to let a small cap stock name their company in a press release if it is not real and substantial.

Yesterday’s release went a step further than that: A Dell spokesperson is even quoted in the release. I will show you the quote… but I encourage you to read the full press release below.

Here is that quote:

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

Then the release quotes Vicor CEO David Fater:

“We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater.

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer™ to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer™ and PD2i CA™ worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

Obviously this is a huge development. Read the full release. Read my disclosure at the bottom. I still hold all shares.

HERE IS THE FULL RELEASE:

Vicor Technologies’ Selects Dell to Serve as Worldwide IT Hardware Partner for Its PD2i Analyzer(TM)

BOCA RATON, FL, Oct 06, 2010 (MARKETWIRE via COMTEX) — David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced that Vicor has selected Dell’s Healthcare and Life Sciences division to serve as its worldwide hardware partner for the Company’s PD2i Analyzer(TM) and PD2i CA(TM) (Cardiac Analyzer). According to the terms of the agreement, Dell will create Vicor-labeled laptop computers specifically customized to Vicor’s specifications and package them for Vicor’s worldwide distribution. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i(R) nonlinear algorithm and software. Vicor Technologies is a biotechnology company focused on the development of innovative, non-invasive medical devices using its patented, proprietary PD2i(R) nonlinear algorithm and software. Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events, including congestive heart failure patients for cardiac death resulting from arrhythmia or pump failure, diabetics for diabetic autonomic neuropathy (DAN), and trauma victims for imminent death absent immediate lifesaving intervention.

“Dell Healthcare and Life Sciences is proud to be chosen as Vicor’s worldwide IT solutions provider. Dell is committed to developing and supporting healthcare IT solutions to improve care and delivery,” stated Scott Jenkins, PhD, Vice President, Dell, Inc.

“We’re thrilled to have Dell as our worldwide IT solutions partner. Dell’s well-established reputation for creating innovative technologies and business solutions, strong internal development capabilities, global reach, and consumer-centric approach make it the perfect worldwide IT solutions partner for Vicor,” stated Mr. Fater.

“Given the growing amount of positive feedback we’re receiving from physicians and cardiologists using the PD2i Analyzer(TM) to enhance diagnosis of those at risk of cardiac death from arrhythmia or pump failure, as well as autonomic neuropathy, we’re extremely optimistic about the prospects for the PD2i Analyzer(TM) and PD2i CA(TM) worldwide. These diagnostics have enabled the physicians and cardiologists using them to use existing CPT codes for reimbursement, strengthened their ability to diagnose difficult to identify conditions, and enabled early, sometimes life-saving treatment,” Mr. Fater concluded.

About Vicor Technologies, Inc. Vicor Technologies is focused on commercializing innovative non-invasive diagnostics employing its patented, proprietary point correlation dimension algorithm (PD2i(R)). The PD2i(R) nonlinear algorithm is a deterministic, nonlinear measure of electrophysiological potentials that predicts future pathological events with a high degree of accuracy in target populations.

The PD2i Analyzer(TM), which has FDA 510(k) marketing clearance, measures heart rate variability. Physicians performing diagnostic tests with the PD2i Analyzer(TM) are able to receive reimbursement under existing CPT codes. The PD2i VS(TM) (Vital Sign), in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research (http://www.usaisr.amedd.army.mil/), risk stratifies combat and civilian trauma victims. The PD2i CA(TM) (Cardiac Analyzer), in various clinical trials, identifies patients at elevated risk of cardiac death resulting from arrhythmia or pump failure.

Vicor anticipates developing additional applications utilizing the PD2i(R) nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases. Additional information is available at www.vicortech.com.

Disclaimer The appearance in this release of name-brand institutions, such as Dell and the U.S. Army Institute for Surgical Research, does not constitute endorsement by these institutions of the information, products, or services contained therein.

Caution Regarding Forward-Looking Statements Forward-looking statements in this press release are based on current plans and expectations that are subject to uncertainties and risks, which could cause our future results to differ materially. The following factors, among others, could cause our actual results to differ: our ability to generate revenues from the sale of the PD2i Analyzer(TM); our ability to obtain FDA approval of our 510(k) submission to secure a marketing claim for the PD2i CA(TM)(Cardiac Analyzer) for testing patients for cardiovascular disease and our ability to obtain marketing clearance from the FDA for the PD2i VS(TM) (Vital Sign) for military and civilian applications; our ability to obtain the necessary regulatory approvals to market in the People’s Republic of China; our ability to develop additional applications for the PD2i(R) algorithm; our ability to continue to receive financing sufficient to continue operations and complete critical clinical trials; our ability to continue as a going concern; our ability to successfully develop products based on our technologies; our ability to successfully complete the normal range study for PD2i(R) values; our ability to obtain and maintain adequate levels of third-party reimbursement for our products; the impact of competitive products and pricing; our ability to receive regulatory approval for our products; the ability of third-party contract research organizations to perform preclinical testing and clinical trials for our technologies; the ability of third-party manufacturers to manufacture our products; our ability to retain the services of our key personnel; our ability to market and sell our products successfully; our ability to protect our intellectual property; product liability; changes in federal income tax laws and regulations; general market conditions in the medical device and pharmaceutical industries; and other matters that are described in Vicor’s Annual Report on Form 10-K for the fiscal year ended December 31, 2009 and subsequent filings with the Securities and Exchange Commission. Forward-looking statements in this press release speak only as of the date of the press release, and we assume no obligation to update forward-looking statements or the reasons why actual results could differ.

Release 10-18

CORPORATE CONTACT

David H. Fater

Vicor Technologies, Inc.

561.995.7313

dfater@vicortech.com

INVESTOR CONTACT

Richard Moyer

Cameron Associates

212.554.5466

richard@cameronassoc.com

MEDIA CONTACT

Robin Schoen

Robin Schoen Public Relations

215.504.2122

schoenpr@comcast.net

….

Pentony Enterprises LLC is BOLD STOCKS AND STOCKGURU.COM. 1601 Berwick Drive, McKinney, Texas 75070. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period.  As of October 7, 2010 we have not bought or sold any shares. We still hold all shares in certificate form with the restrictive legend still in place.

Bold Stock Alert: Vicor Technologies, Inc. (OTCBB: VCRT) is our Newest Bold Stock!

>>> DO BOLD STOCKS PERFORM WELL? SEE OUR RESULTS HERE <<<

Dear Bold Members:

Let me start by saying that our affiliated site, StockGuru.com has initated coverage on Vicor Technologies as well just yesterday. A bigger name in stock market research also announced coverage yesterday. Did you see this headline from Standard & Poors:

Standard & Poor’s Initiates Factual Stock Report Coverage on Vicor Technologies

READ THE PRESS RELEASE HERE

Volume yesterday was very strong. Of course the stock closed up.

MUCH MORE IMPORTANLY, THIS IS A COMPANY THAT IS OUT TO SAVE LIVES

Here is part of the StockGuru Profile on VCRT

Vicor Technologies, Inc. (OTCBB: VCRT) is in the crucial transformative stage for a biotechnology company on the verge of becoming a viable commercial enterprise.

This biotechnology company is focused on the commercialization of innovative, non-invasive medical devices and diagnostics using its patented, proprietary PD2i™ nonlinear algorithm and software which is:

• Highly accurate
• Provides user friendly data acquisition
• Effective for trauma triage easily deployed in a portable monitor
• Provides a simple noninvasive test for identifying patients at risk of sudden cardiac death
• Provides a simple noninvasive test for identifying patients with Diabetic Autonomic Neuropathy

The PD2i Algorithm and software risk stratifies target populations to predict future pathological events. As a predictor of sudden cardiac death it has been shown to be highly accurate, with a sensitivity approaching 100% and a specificity of ~86%.

The advantage of the PD2i™ nonlinear algorithm is that it typically uses recordings made at rest and does not require stress-testing or any active participation from the patient. The test is relatively impervious to data non-stationarities and artifacts, setting it apart from other measures with unparalleled sensitivity.

A large physician shareholder base represents the early adoptees of this Company.

Vicor’s PD2i™ Nonlinear Algorithm is:

• A new vital sign with the ability to actually save lives in both combat and civilian setting
• The PD2i Analyzer™ can capture and display Heart Rate Variability (see defined below) in patients at rest and during paced respiration and controlled exercise.
• Able to identify trauma victims in need of an immediate lifesaving intervention
• Able to be used along with other clinical data to identify patients at risk of sudden cardiac death
• Able to be used along with other clinical data to identify patients who have autonomic dysfunction
• Able to improve trauma triage in real world situations and on the battlefield where time is of the essence and the collection of ‘clean’ data is never guaranteed
• Able to provide consistently accurate results which requires just one to two minutes of EKG data in a trauma setting
• Not derailed in delivering actionable results by noisy raw EKG data
• Functional in trauma environments and battlefield situations

Vicor’s Three Products Employing the PD2i™ Nonlinear Algorithm.

• PD2i Analyzer(TM) has FDA 510(k) marketing clearance. It measures Heart Rate Variability. Physicians performing diagnostic tests with the PD2i Analyzer™ are able to receive reimbursement under existing CPT codes.
• PD2i VS(TM) (Vital Sign) stratifies risk in combat and civilian trauma victims and is in clinical trials under a collaborative effort with the U.S. Army Institute for Surgical Research. (http://www.usaisr.amedd.army.mil/)
• PD2i CA(TM) (Cardiac Analyzer) identifies patients at risk of sudden cardiac death and is in multiple clinical trials.

Vicor anticipates additional applications employing the PD2i™ nonlinear algorithm to enable early detection and risk stratification for a variety of other disorders and diseases.

The PD2i Analyzer™ has been cleared by the FDA for marketing as a measure of Heart Rate Variability. It quantifies the relationship between the patient’s heart and brain by measuring the heart rate variation over time. The PD2i® test is painless and much like a value-added electrocardiogram. Adhesive sensor pads are placed on the skin and for the next twenty minutes the Analyzer records heartbeat information. Exercise is not necessary during the test.

The PD2i Analyzer™ twenty-minute test is composed of recording a sequence of one thousand heartbeats. The PD2i™ nonlinear algorithm is subsequently applied to that recording in order to find subtle patterns in the resulting data, yielding the final result which is expressed as a minimum PD2i™ value.

See that FULL PROFILE HERE.

What I read into this company:

The technology is huge.When you read about this…

PD2i-VS™ Tested by U.S. Army Institute of Surgical Research (USAISR) (Note: Full details ncluded in the StockGuru Profile)

… You begin to realize the company is something special.

Most Boldly,

Mr. Bold

.

.

.

.Bold Stocks (”Bold”) provides its members with the latest news, press releases, and research reports for all the companies highlighted on our web site, www.BoldStocks.com. Bold utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by Bold to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. They may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. Any opinions expressed are subject to change without notice. Bold encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and Bold makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Bold is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed onhttp://www.boldstocks.com or mentioned herein. This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies= annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and Bold undertakes no obligation to update such statements. Pentony Enterprises LLC is occassionally compensated for coverage. When this is the case, we indicate clearly with a disclosure of all compensation received in the past and present, plus we also disclose any anticipated compensation in the future. Compensation is typically in cash. Sometimes a third party shareholder pays us in free trading shares. Sometimes a company pays us in restricted shares. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. VCRT Disclosure: Pentony Enterprises LLC is STOCKGURU.COM. 10604 Robincreek Lane; Frisco, Texas 75035. (469) 252-3030. Disclosure: Pentony Enterprises LLC was compensated fifty thousand restricted common shares and seventy-two hundred dollars by the company for profile coverage for the period ending March 31, 2010. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. We will not be buying or selling shares of Vicor during the promotional period. MZEI Disclosure: Pentony Enterprises LLC was compensated seventy-two hundred dollars and 450,000 144 restricted common shars by the company for profile coverage for the period ending September 15, 2009. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. Disclosure TAXS: Pentony Enterprises LLC is STOCKGURU.COM, SHAREHOLDERVISION.COM and STREETRESEARCH.COM. 9555 Lebanon Road; Suite 103; Frisco, Texas 75035. (469) 252-3030. Disclosure for TAXS: Pentony Enterprises LLC expects to be compensated a total of twenty thousand shares and five thousand dollars from a non-affiliated third party for our coverage of TAXS. Pentony Enterprises is not a registered investment adviser or a broker/dealer. Pentony Enterprises LLC makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.